目的 通過快速評價為醫(yī)療機(jī)構(gòu)遴選原研及國家集采的選擇性5-羥色胺再攝取抑制劑（SSRIs）類抗抑郁藥提供科學(xué)高效的參考依據(jù)，明確其臨床應(yīng)用價值，進(jìn)而初步探究將原研藥品及集采藥品分別評價與二者整合評價之間存在的差異性。方法 應(yīng)用《中國醫(yī)療機(jī)構(gòu)藥品評價與遴選快速指南（第二版）》進(jìn)行初步的評價實(shí)踐，通過藥學(xué)特性、有效性、安全性、經(jīng)濟(jì)性和其他等5個方面分別對原研SSRIs、國家集采SSRIs以及原研合并集采的SSRIs整體進(jìn)行逐項(xiàng)評價。結(jié)果 評價結(jié)果表明可通過快速指南分別對SSRIs的原研藥品及集采藥品進(jìn)行遴選與評價，從而排序出臨床應(yīng)用首選的先后名次，而將原研藥品及集采藥品整合在一起共同評價并不適用。結(jié)論 可應(yīng)用《中國醫(yī)療機(jī)構(gòu)藥品評價與遴選快速指南（第二版）》對相關(guān)藥品進(jìn)行遴選與評價，以便促進(jìn)臨床合理用藥。但是僅限于同一藥品采購分類，即此快速評價并不適用于同一通用名稱的原研藥品、集采藥品同時評價。

Objective The rapid evaluation provides scientific and efficient reference basis for medical institutions to select the innovator drugs and national centralized purchase drugs of SSRIs antidepressants, clarify their clinical application value, and then preliminatively explore the differences between the separate evaluation of the innovator drugs, National centralized purchase drugs and the integrated evaluation of the two. Methods The Rapid Guide for the Evaluation and Selection of Drugs in Chinese Medical Institutions (Second Edition) was applied to conduct preliminary evaluation practice, and the innovator drugs of SSRIs, centralized purchase drugs of SSRIs and the innovator drugs combined with centralized purchase drugs of SSRIs were evaluated one by one through five aspects, such as pharmaceutical characteristics, effectiveness, safety, economy and other aspects. Results The evaluation results showed that the rapid guide could be used to select and evaluate the innovator drugs and the centralized purchase drugs of SSRIs respectively, so as to sort out the priority of clinical application, while the innovator drugs combined with centralized purchase drugs of SSRIs were not suitable for this evaluation. Conclusion This article shows that the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) can be applied to select and evaluate related drugs in order to promote rational clinical use of drugs. However, this rapid evaluation is limited to the same drug procurement classification, that is, this rapid evaluation does not apply to the original drug of the same generic name, the collective drug evaluation at the same time.

R749